VivoSeq
Other

Consolidation Therapy

0

Pipeline Programs↗

8

Active Trials↗

1

Companies Involved↗

Consolidation Therapy is an early-stage landscape with 0 programs across 1 company. The most active players are Kiromic BioPharma Inc..

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kiromic BioPharma Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Recruiting6 · 50%
Not yet recruiting2 · 17%
Terminated2 · 17%
Unknown status1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

12 trials

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04992559·41 enrolled
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT05758116·20 enrolled
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
Recruiting·SSun Yat-sen University·Phase 2/3·NCT05623267·346 enrolled
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Recruiting·—·Phase 2·NCT07108998·22 enrolled
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
Recruiting·ZZhujiang Hospital·Phase 1/2·NCT07072494·30 enrolled
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06232694·54 enrolled
Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07443488·20 enrolled
Effects of Peginterferon Consolidation Therapy on Hepatic cccDNA Dynamics in CHB Patients Achieving Clinical Cure.
Not yet recruiting·XXiamen Hospital of Traditional Chinese Medicine·N/A·NCT06920329·30 enrolled
Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years
Terminated·PPETHEMA Foundation·Phase 2·NCT01193400·75 enrolled
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
Terminated·PrECOG, LLC.·Phase 1/2·NCT01656252·15 enrolled
Consolidation Therapy in Patients With Metastatic Solid Malignancies
Withdrawn·KKiromic BioPharma Inc.·Phase 1/2·NCT02705703
BL-8040 Addition to Consolidation Therapy in AML Patients
Unknown status·—·Phase 2·NCT02502968·194 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)